Phase II Study of Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer Resistant to Endocrine Therapy
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 9
- 试验地点
- 8
- 主要终点
- Clinical Benefit Rate (CBR)
研究概览
简要总结
The purpose of the trial is to investigate the efficacy of metronomic treatment with daily oral vinorelbine in terms of clinical benefit rate based on local radiological assessment in patients with advanced/metastatic HR+/HER2- breast cancer resistant to endocrine therapy.
详细描述
In terms of the chronic nature of advanced/metastatic breast cancer, there is a high medical need for new treatment options after failure of hormonal treatment that prolong the interval to the start of intensive cytotoxic therapy, which is commonly associated with impaired quality of life (QoL) and potentially serious side effects. In this respect, metronomic treatment with daily administration of oral vinorelbine could provide an efficacious treatment option with limited toxicities.
Accordingly, this national, multi-centre, open-label, single-arm phase II trial aims to investigate a truly metronomic schedule with daily oral vinorelbine in HR+/HER2-patients with metastatic breast cancer resistant to endocrine therapy, by assessing efficacy and safety. Oral vinorelbine will be administered at a daily dose of 30 mg (flat dose without any adaptation to body weight or body surface area) without breaks. Treatment will continue until disease progression, occurrence of unacceptable toxicity, patient's refusal or investigator's decision to stop the treatment.
In the course of the study, the following interim and final analyses will be done:
i) 1st interim analysis (safety): This analysis will be performed on the basis of 10 patients, who were initially included into the study and who are eligible for safety evaluation; frequency statistics of (serious) adverse events will be analysed.
ii) 2nd interim analysis (efficacy): This analysis will be performed at the completion of the 1st Simon stage.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Written (personally dated and signed) informed consent prior to the performance of any trial specific procedure
- •Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and/or the follow-up schedule
- •Female patient ≥ 18 years of age
- •Eastern Cooperative Oncology Group (ECOG) performance status 0-1, which the investigator assesses as being stable at time of screening
- •Estimated life expectancy ≥ 16 weeks
- •Histologically confirmed adenocarcinoma of the breast
- •Documented locally advanced or metastatic disease, previously untreated by palliative chemotherapy and not amenable to any curative treatment
- •Hormone receptor positive disease determined by ≥ 1% positive stained cells for oestrogen and/or progesterone receptor by immunohistochemistry on the primary tumour or on a metastatic site
- •HER2-negative disease assessed by 0-1+ immuno-histochemistry (IHC) or 2+ IHC with negative fluorescence in situ hybridization (FISH) or CISH) on the primary tumour or on a metastatic site
- •Availability of archival (from the most recently obtained sample) or fresh tumour tissue from patients included in the trial for the analysis of relevant metronomic biomarkers; one tumour block (preferred) or a minimum of 12 (recommended: 15) unstained slides to be provided
- •Relapse ≤ 12 months from end of adjuvant hormonal therapy or pro¬gres¬sion during/after ≥ 1 line of endocrine therapy in the metastatic set¬ting and/or no longer candidate for further endocrine therapy
- •Prior (neo-)adjuvant chemotherapy is allowed, if the interval between end of chemotherapy and date of registration is > 12 months
- •Prior treatment with everolimus and/or palbociclib in the frame of hormonal therapy is allowed
- •Complete staging before registration (CT/MRI thorax and CT/MRI abdomen/pelvis ≤ 28 days before registration; bone scan ≤ 3 months before registration)
- •Presence of ≥ 1 measurable lesion as per RECIST 1.1, which has not been previously irradiated
- •Adequate bone marrow, hepatic and renal function as defined by the following laboratory values:
- •Absolute neutrophil count (ANC) ≥ 1,500/mm3
- •Platelet count ≥ 100,000/mm3
- •Haemoglobin ≥ 10 g/dL
- •Total serum bilirubin ≤ 1.5 x upper limit of normal (ULN) (≤ 3 x ULN in case of liver metasta¬s¬es)
- •Liver transaminases ≤ 2.5 x ULN (≤ 5 x ULN in case of liver metasta¬s¬es)
- •Alkaline phosphatase ≤ 5 x ULN
- •Creatinine ≤ 1.5 x ULN (creatinine clearance should be assessed based on the Cockcroft-Gault-formula in case of borderline values and should then be ≥ 50 ml/min)
- •Women of childbearing potential must be using a medically accepted method of contraception to avoid pregnancy during 2 months preceding registration, throughout the study period and up to 3 months after last dose of study treatment in such a manner that the risk of pregnancy is minimised; reliable contraception comprises sexual abstinence, male sterilization or double barrier methods (e.g. a combination of male condom with diaphragm).
- •Women of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to start of study treatment
- •Ability of the patient to understand the character and the individual consequences of this clinical trial.
排除标准
- •No recovery to ≤ Grade (G)1 side effects (exception: alopecia) of any prior anti-neoplastic treatment
- •Aggressive locally advanced or metastatic breast cancer disease requiring systemic combination therapy
- •Known or suspected central nervous system (CNS) and/or leptomeningeal involvement
- •Current peripheral neuropathy ≥ G2
- •Dysphagia or inability to swallow oral medication
- •Malabsorption syndrome or disease significantly affecting GI-function or major resection of the stomach or proximal small bowel that could affect absorption of oral vinorelbine
- •Other serious illness or medical condition, such as but not limited to:
- •Clinically significant cardiac disease or impaired cardiac function (such as: congestive heart failure requiring treatment (NYHA ≥ II); eft ventricular ejection fraction (LVEF) < 50%; significant cardiac arrhythmia; atrial fibrillation; conduction abnormality such as congenital long QT syndrome or high grade/complete atrioventricular (AV)-blockage; acute coronary syndrome including myocardial infarction, unstable angina pectoris, coronary artery bypass graft, coronary angioplasty or stenting, if < 3 months prior to registration; QTcF > 480 msec at screening)
- •Uncontrolled hypertension (> 140/100 mmHg at rest (average of 3 consecutive readings))
- •Unstable diabetes mellitus
- •Uncontrolled hypercalcemia
- •Clinically significant active infections (current or within the last 2 weeks prior to registration)
- •Previous organ allograft
- •Prior treatment with vinorelbine or other vinca alkaloids
- •Concomitant endocrine therapy (e.g. tamoxifen, aromatase inhibitors, fulvestrant) for advanced breast cancer
- •Concomitant use of yellow-fever vaccination or other attenuated life vaccine
- •Concomitant treatment with strong CYP3A4-inhibitors or strong CYP3A4-inducers (discontinuation before registration is acceptable, if medically feasible and ethically acceptable)
- •Necessity to undergo long-term oxygen therapy
- •Major surgery ≤ 28 days prior to registration and/or no recovery from side effects of such therapy to baseline condition or ≤ G1
- •Radiotherapy ≤ 28 days prior to registration, no recovery from side effects of such therapy to baseline condition or ≤ G1 and/or irradiation of ≥ 30% of bone marrow
- •Known hypersensitivity to vinca alkaloids, soy, peanut or any of the excipients contained in the oral vinorelbine capsules
- •Participation in another clinical trial with any investigational drug ≤ 30 days prior to registration
- •History of another malignancy within the past 5 years prior to registration, except cured basal cell carcinoma of the skin or cured in-situ carcinoma of the cervix
- •Pregnant or nursing (lactating) woman
研究组 & 干预措施
Vinorelbine Oral
Test product: Navelbine® 20 mg / 30 mg soft capsules
干预措施: Vinorelbine (Drug)
结局指标
主要结局
Clinical Benefit Rate (CBR)
时间窗: 24 weeks after start of treatment.
The primary endpoint is the determination of the Clinical Benefit Rate (CBR) at 24 weeks after start of treatment. The response to treatment is measured by computer tomography (CT) or magnetic resonance imaging (MRI) for measurable lesions and evaluation for non-measurable lesions at 24 weeks after start of treatment.
次要结局
- Time to treatment failure (TTF)(6 months after last patient last treatment)
- Overall response rate (ORR)(6 months after last patient last treatment)
- Disease control rate (DCR)(6 months after last patient last treatment)
- Duration of response (DoR)(6 months after last patient last treatment)
- Number of patients with treatment-related adverse events as assessed by CTCAE v4.0(6 months after last patient last treatment)
- Patient's symptoms and health-related quality of life(6 months after last patient last treatment)
- Duration of stable disease (DoSD)(6 months after last patient last treatment)
- Histopathological parameters(before start of treatment and upon progression, assessed up to 6 months after last patient last treatment)
- Duration of disease control (DoDC)(6 months after last patient last treatment)
- Overall survival (OS)(6 months after last patient last treatment)
- Biomarker profiles(before start of treatment, during treatment period and upon progression, assessed up to 6 months after last patient last treatment)
- Progression-free survival (PFS)(6 months after last patient last treatment)
研究者
Marcus Schmidt, MD
Univ.-Prof. Dr. med.
Johannes Gutenberg University Mainz